To The Moon

The $S&P 500(.SPX)$ and $NASDAQ(.IXIC)$ reaching record highs in mid-2026 is driven largely by resilient corporate earnings and massive AI infrastructure spending. However, the market currently faces a "brittle" environment where high valuations leave little room for error. Below is an analysis of the impending risks and strategies to manage a portfolio in this high-altitude environment. 1. Impending Risks (May 2026) Despite the bullish momentum, several "flashpoints" could trigger a sudden correction: Geopolitical Volatility: The ongoing conflict in Iran remains a primary risk. While markets have recently shown a "faster recovery" from geopolitical shocks, a prolonged naval blockade or escalation co

$Baidu(BIDU)$ is scheduled to report its fiscal Q1 2026 results on Monday, May 18, 2026, before the U.S. market opens. This quarter is being viewed as a significant "inflection point" where the company's long-term AI investments are expected to finally counterbalance a maturing and volatile advertising market. Baidu (BIDU) reported its fiscal Q4 2025 results on February 26, 2026. The quarter was described by management as the "singularity" moment where AI officially became the core driver of the company’s business model. Summary of Q4 2025 Financials Total Revenue: RMB 32.7 billion ($4.68 billion), up 5% quarter-over-quarter (QoQ). While quarterly growth was steady, annual revenue for 2025 was down 3% YoY due to the drag from legacy businesses. Ea

Cerebras Systems Shakes The AI Kingdom  🌟🌟🌟The tectonic plates of the technology sector has just shifted with the official public debut of $Cerebras Systems Inc.(CBRS)$ on May 14 2026.  Cerebras is a pure play AI chipmaker which could be a big rival to NVIDIA. This wasn't a standard IPO.   It was an institutional stampede.  Its performance has sent shockwaves through Silicon Valley, proving that Wall Street's insatiable hunger for AI infrastructure has entered a dramatic new paradigm. Cerebras' Historic IPO Performance  The numbers surrounding Cerebras debut are staggering, resulting in one of the most explosive public openings in the history of the semiconductor industry. The Unprecedented Pricing: Having initi

The Case for Novo Nordisk at a Distressed Multiple Novo Nordisk has had the sort of year that makes investors check their portfolios twice just to confirm the numbers are real. The shares have collapsed from a 52-week high of 81.44 to the mid-40s, sentiment has deteriorated sharply, and a company once treated like Europe’s growth crown jewel is now trading at barely 10–11 times earnings. That disconnect is exactly why I think the opportunity has become so compelling. Markets see collapse. The fundamentals suggest strategic transformation The market is behaving as though Novo’s growth engine has permanently stalled. I believe something very different is happening: the company is transitioning from a blockbuster obesity story into a broader cardiometabolic platform, while simultaneously open

$SPDR S&P 500 ETF Trust(SPY)$ Following the bullish 800 calls, SPY is now seeing a new wave of aggressive long positions — large blocks of deep OTM call options:$SPY 20271217 1095.0 CALL$  $SPY 20271217 1100.0 CALL$  $SPY 20271217 1110.0 CALL$  $SPY 20271217 1120.0 CALL$ . Total premium flow: under $8 million. These December 2027 expiries (1095, 1100, 1110, 1120 strikes) each saw 10,000 contracts opened on Wednesday, direction buys. These calls have deltas below 0.1 — e

👋 Hey Tigers! The F4Q26 earnings report for $Alibaba(BABA)$ is in. Here's what the Tiger Research Team is saying: 👉 Maintain BUY rating 👉 Price Target maintained at $175 📈 👉 Latest Price as of May 13th: $144.22 The quarter was strategically encouraging but financially messy — revenue and profits missed estimates meaningfully, yet AI and cloud commercialization showed acceleration. Here's the breakdown 👇 1. F4Q26 Financial Check: The Numbers vs. Estimates 📉 Revenue: 📊 Revenue of RMB243.4bn was 4% below Tiger estimates (RMB253.5bn) and 1% below consensus (RMB247.0bn) The miss was partly due to reclassification of certain merchant subsidies from sales & marketing expense to contra-CMR Profitability (the main negative): 📉 Gross profit of RMB84.0bn

👋 Hey Tigers! The 1Q26 earnings report for Tencent Holdings ( $TENCENT(00700)$ ) is in. Here's what the Tiger Research Team is saying: 👉 Maintain BUY rating 👉 Price Target decreased to HK$690 (was HK$700) 📈 👉 As of May 13th Price: HK$457.20 The quarter was strategically positive and financially solid — revenue was slightly light on timing, yet profits beat estimates. More importantly, core businesses remain highly cash generative while AI is moving from a broad strategic narrative into visible product deployment and early monetization. Here's the breakdown 👇 1. 1Q26 Financial Check: The Numbers vs. Estimates 📊 Revenue: 📊 Revenue of RMB196.5bn was 3% below Tiger estimates (RMB203.2bn) and 1% below consensus (RMB197.6bn) The miss was partly due to